Intravenous and intratumoral treatment with TILT-123 was found to be safe and feasible, with no dose-limiting toxicities when given alone or in combination with tumor infiltrating lymphocyte therapy in patients with advanced, metastatic melanoma.
New research from Copenhagen University Hospital – Rigshospitalet and Herlev and Gentofte Hospital has shed new light on the immune system’s complex struggle against the coronavirus.